Antibody

4개 · ADC 882 · Antibody 4071 · CGT 2714 · 자동 수집 갱신 권장 · 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved4 programs

데이터 갱신 주기입니다. 갱신 대기 7,666개 보기 · Curated Core는 주간 자동 동기화됩니다.

AntibodyLimited DatastaleRochePhase 2

atezolizumab (Tecentriq, Atezolizumab - 28 Day Cycle)

Endometrial Cancer · Endometrial Cancer

#EndometrialCancer#Antibody#Phase2#Popular#monoclonal-antibody+2
Trials 53Status Recruiting
AntibodyLimited DatastaleRochePhase 2

atezolizumab (Tecentriq, Atezolizumab - 21 Day Cycle)

Endometrial Cancer · Endometrial Cancer

#EndometrialCancer#Antibody#Phase2#monoclonal-antibody#oncolyticvirus-basedimmunostimul+1
Trials 31Status Recruiting
AntibodyLimited DatastaleFox Chase Cancer CenterPhase 2

pembrolizumab (Keytruda, Epacadostat + pembrolizumab)

Recurrent/ Metastatic Endometrial Carcinoma · Recurrent/ Metastatic Endometrial Carcin

#RecurrentMetastaticEndometrialCa#Antibody#Phase2#monoclonal-antibody#Recurrent+2
Trials 1Status Discontinued
AntibodyLimited DatastaleInnoventPreclinical

pembrolizumab (Keytruda, MPA, Sintilimab or Pembrolizumab and medroxyprogesterone acetate, Sintilimab or Pembrolizumab and medroxyprogesterone acetate (MPA)/ megestrol acetate (MA))

Endometrial Cancer; Endometrioid Carcinoma · Endometrial Cancer

#EndometrialCancer#Antibody#Preclinical#monoclonal-antibody#EndometrioidCarcinoma+1
Trials 1Status Recruiting